Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/01/2003US20030083352 Cyclization of a 2-cyano-2-ester-ethylenamine with a primary amine to a 4-ester imidazole
05/01/2003US20030083348 Farnesyl transferase inhibitors
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083335 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP)
05/01/2003US20030083332 N-heterocyclic derivatives as NOS inhibitors
05/01/2003US20030083319 For treating osteoporosis, secondary hyperparathyroidism, cancer and autoimmune diseases without inducing hypercalciuria, hypercalcemia, or nephrotoxicity
05/01/2003US20030083316 Dioxolane nucleosides and nucleoside analogues such as troxacitabine together with chemotherapeutic agents other than doxorubicin such as cytarabine, gemcitabine and idarubicin; synergistic mixture; treating leukemia, cancer
05/01/2003US20030083313 Means of tumor therapy
05/01/2003US20030083296 Antisense modulation of caspase 8 expression
05/01/2003US20030083294 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
05/01/2003US20030083286 Comprises penetration enhancer (fatty acid); drug delivery; increases bioavailability of oligonucleotides
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083271 Such as 12-(6-deoxy-6-fluoro-D-galactopyranosyl)-3,9-difluoro-12,13-dihydro-5H -indolo(2,3-a)pyrrolo(3,4-c)carbazole -5,7(6H)-dione for inhibiting proliferation of tumor cells
05/01/2003US20030083265 TGF-beta inhibitors and methods
05/01/2003US20030083264 A peptide having the amino acid sequence proline, histidine, serine, arginine, and asparagine
05/01/2003US20030083256 Compositions and methods for enhancing drug delivery across and into epithelial tissues
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083252 Neuronal uses of BMP-11
05/01/2003US20030083246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule
05/01/2003US20030083242 Methods and compositions for treating or preventing peripheral neuropathies
05/01/2003US20030083239 Hexapeptide capable of inhibiting beta-chemokine from binding to CCR3 receptor; for treating subject with a disease associated with aberrant leukocyte recruitment and/or activation
05/01/2003US20030083235 Such as alpha-O-linked glycopeptides with clustered glycodomains which are useful as anticancer agents
05/01/2003US20030083229 Isolating T cells from mammal, incubating cells with protein expression product of activated oncogene or cancer-related gene associated with malignancy, detecting presence or absence of proliferation of T cells, determining malignancy
05/01/2003US20030082786 PEG-modified uricase
05/01/2003US20030082769 Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor binding pocket
05/01/2003US20030082748 Nucleotide sequences coding polypeptides for use in the treatment of leukemia, tumors, psoriasis, chronic infections, autoimmune and fibrotic disorders; wound healing agents
05/01/2003US20030082725 DNA encoding a novel human inhibitor-of-apoptosis protein
05/01/2003US20030082722 Method for amplifying expression from a cell specific promoter
05/01/2003US20030082685 Chemotherapeutic induction of egr-1 promoter activity
05/01/2003US20030082643 Human monoclonal antibodies to FC alpha receptor (CD89)
05/01/2003US20030082622 Crystalline polypeptide for use in the treatment of tumor and cardiovascular and respiratory system disorders
05/01/2003US20030082620 Novel human genes and gene expression products: II
05/01/2003US20030082612 Detection of mutant leptin receptor; obtain cells, extract nucleotide sequences, incubate with an oligonucleotide probe, detect hybridization, presence of hybridization, indicates defective receptor
05/01/2003US20030082609 Nuceotide sequences coding polypeptide for use in humans therapeutics and diagnostics
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082234 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
05/01/2003US20030082224 Antitumor, anticancer agents
05/01/2003US20030082207 Method of using HIV protease inhibiting compounds
05/01/2003US20030082201 Genetic engineering; polymerase chain reaction
05/01/2003US20030082195 Method of enhancing an immune response
05/01/2003US20030082184 Uses of mammalian cytokine; related reagents
05/01/2003US20030082175 April receptor (BCMA) and uses thereof
05/01/2003US20030082172 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
05/01/2003US20030082166 Compounds and methods for modulating nonclassical cadherin-mediated functions
05/01/2003US20030082160 Differentiation of whole bone marrow
05/01/2003US20030082150 Recombinant adenoviral vectors for human tumour gene therapy
05/01/2003US20030082143 Filamentous phage particles having a ligand on surface for delivering a therapeutic gene to a cell; gene therapy
05/01/2003US20030082140 Increasing the amount of the cell differentiation associated protein, MDA-7 and decreasing RAS gene activity by administering a viral vector comprising an MDA-7 gene and an antisense ras oligonucleotide; treating pancreatic cancer
05/01/2003US20030082107 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
05/01/2003US20030082105 Selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions
05/01/2003US20030079311 Suspension bushing, motor vehicle and a suspension cross-member for a motor vehicle
05/01/2003CA2498591A1 Immunotherapy for reversing immune suppression
05/01/2003CA2471532A1 A synthetic chimeric fusion protein with immuno-therapeutic uses
05/01/2003CA2466813A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003CA2464790A1 Treatment of acute myeloid leukemia with indolinone compounds
05/01/2003CA2464700A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
05/01/2003CA2464695A1 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003CA2464593A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003CA2464394A1 Methods and compositions for inducing tumor-specific cytotoxicity
05/01/2003CA2464349A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464311A1 Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
05/01/2003CA2464271A1 Integrin targeting compounds
05/01/2003CA2464254A1 Inhibitors of post-proline cleaving proteases
05/01/2003CA2464239A1 Psma antibodies and protein multimers
05/01/2003CA2463923A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same
05/01/2003CA2463902A1 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003CA2463101A1 Azole derivatives and pharmaceutical compositions containing them
05/01/2003CA2461661A1 Use of histamine to treat liver disease
05/01/2003CA2461085A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
05/01/2003CA2460680A1 Substituted indazole compounds for the treatment of inflammation
05/01/2003CA2458958A1 Method and apparatus for dispensing inhalator medicament
04/2003
04/30/2003CN1414970A Transgenically produced fusion proteins
04/30/2003CN1414956A Substituted piperazine derivatives as MIP inhibitors
04/30/2003CN1414954A Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof
04/30/2003CN1414952A Heterocyclic compounds having sulfonic acid
04/30/2003CN1414865A 癌症的治疗 Treatment of cancer
04/30/2003CN1414864A Adhesive particle DNA constructs and method of making and using the same
04/30/2003CN1414858A Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound
04/30/2003CN1414854A Phosphonate compounds
04/30/2003CN1414849A Carboxylic acid amides, medicaments containing these compounds and the use and preparation thereof
04/30/2003CN1414010A Cardiac glycoside type compound for treating carcinosis and its preparation method
04/30/2003CN1413731A Macrophage tumor vaccin and its preparation method
04/30/2003CN1413695A Medicine for treating leukopenia caused by carcinosis radiotherapy and chemotherapy
04/30/2003CN1413674A Health-care liquid, powder for antitumor and prevention and curing
04/30/2003CN1413661A Chinese medicine capsule and external used medicine for treating skin carcinoma and its preparation method
04/30/2003CN1413659A Chinese medicine capsule and adhesive plaster for treating mammary cancer and its preparation method
04/30/2003CN1413657A Chinese medicine capsule, pill for treating liver cancer and preparation method
04/30/2003CN1413652A Specific remedy for hysteromyoma and preparing method
04/30/2003CN1413646A Antitumor oral liquid and its preparation method
04/30/2003CN1413608A Discorea nipponica and new use of its active component
04/30/2003CN1413590A Cancer prevention oral medicine
04/30/2003CN1413584A Antitumor oral medicine prepared by Chinese yew extract
04/30/2003CN1413581A Pharmaceutical preparation containing northeast cryrtominetin medicinal preparation and its new use
04/30/2003CN1413580A Elemene antitumor medicine and its preparation method
04/30/2003CN1107068C 2-amino-7-(1-substituted-2-hyroxyethyl)-3.5-diphydro-pyrrolo (3,2-D) pyrimidine-4-ones
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106858C Vaccine composition having antitumour activity and use there of in therapy of malignant diseases
04/30/2003CN1106855C Oral liquid for treating digestive system tumor
04/30/2003CN1106836C Sustained release and implantation type fluorouracil medicine and method for preparing same